Hi RL,
Are you please able to post how you come to this conclusion with your thoughts that in the lower albuminuria group, their levels went up - as in your maths working out? I’m genuinely interested.
It was noted in the investor call that patients in this lower cohort had an average of 14% reduction in albuminuria on treatment, but a confounding factor of 12% reduction while on placebo, which is where this 2% comes in & what they will be looking at in terms of legacy effect on placebo & also concomitant medication (particularly SGLT2s).
Someone actually asked that question in the investor call - did the albuminuria levels go up in the lower baseline albuminuria group (<500mg/g) and Professor Packham said NO.
I’m sorry to see you go RL, I have been enjoying your posts.
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-320
-
-
- There are more pages in this discussion • 308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.8¢ |
Change
-0.008(1.95%) |
Mkt cap ! $211.6M |
Open | High | Low | Value | Volume |
38.5¢ | 39.3¢ | 37.3¢ | $643.1K | 1.675M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 136653 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 36468 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 136653 | 0.375 |
13 | 193774 | 0.370 |
7 | 137324 | 0.365 |
12 | 200187 | 0.360 |
7 | 188139 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 36468 | 4 |
0.385 | 88614 | 6 |
0.390 | 103288 | 7 |
0.395 | 366154 | 8 |
0.400 | 147196 | 6 |
Last trade - 14.52pm 30/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |